Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
REGULATORY
MOF Panel Begins Debate for FY2025 Budget Proposal, Mulls Spending Target
A key Japanese finance ministry panel on April 4 launched discussions on a policy recommendation towards FY2025 budgets. The focus is how the government would set its spending target for the next fiscal year and beyond. The so-called “spring recommendation”…
To read the full story
Related Article
- MOF Panel Wants Prioritized Budgeting for Drug Costs: Subcommittee Acting Chair
December 2, 2024
- MOF Panel Urges Annual Price Revisions on All Drugs in 2025 Budget Proposal
November 29, 2024
- MOF Stands Firm on Push for Full-Scale Off-Year Revision in FY2025
November 14, 2024
- MOF Panel Urges Full-Scale Off-Year Revisions, Enhanced CEA: “Spring” Proposal
May 22, 2024
- MOF Ramps Up Push for Use of Cost-Effectiveness Assessment in Reimbursement Decisions
April 17, 2024
REGULATORY
- NCC President Nakagama to Lead AMED from April
March 26, 2025
- Pariet’s Nonprescription Versions Approved 6 Years after Discussions Start
March 25, 2025
- AMED President Mishima Hints at Resignation
March 25, 2025
- FPMAJ Prods Drastic Review of Fiscal Framework before Honebuto 2025
March 25, 2025
- Difficult to “Visualize” Distribution, Production Costs in NHI Prices: Minister
March 25, 2025
The global race to develop so-called “double G” and “triple G” agonists is heating up to boost the efficacy of…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…